The Northeast ALS Consortium
Highly Engaged Employees
Highly Engaged EmployeesNon-Profit & Charitable Organizations · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1155 Walnut St Ste 23, Newton Highlands,...Phone Number
(617) 858-4277Website
www.neals.orgRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About The Northeast ALS Consortium
NEALS is a global network dedicated to accelerating the discovery and delivery of effective treatments for Amyotrophic Lateral Sclerosis (ALS) through collaborative research and education. The organization connects researchers, clinicians, and individuals living with ALS to enhance clinical trial capabilities and provide educational resources. NEALS offers a platform for finding clinical studies and specialists, as well as hosting community education webinars. Their mission focuses on improving and extending the lives of people affected by ALS by fostering innovation in research and treatment.Explore more
The Northeast ALS Consortium Org Chart
CA
Program Director
JH
Administrative Coordinator
LV
Legal Assistant
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is The Northeast ALS Consortium your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if The Northeast ALS Consortium is spiking on competitors!
Product Launch: Get notified when The Northeast ALS Consortium launches new products
The Northeast ALS Consortium, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if The Northeast ALS Consortium had a recent Job posting/layoffs
Check if The Northeast ALS Consortium has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on The Northeast ALS Consortium recently announced quarterly report
Funding: Get notified immidiatlly once The Northeast ALS Consortium has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at The Northeast ALS Consortium
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to The Northeast ALS Consortium
Compare insights from companies similar to The Northeast ALS Consortium, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
The Northeast ALS Consort...
<$5M
1-10
Private
-
2005
CS
Christina SmithCommunications & Outreach Coordinator & Program Manager, Crli
Company Profile Activity
Activity Insights
The Northeast ALS Consortium is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
The Northeast ALS Consortium is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about The Northeast ALS Consortium.
The Northeast ALS Consortium Tech Stack
A closer look at the technologies used by The Northeast ALS Consortium
The Northeast ALS Consortium News & Media
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
Biomarker data suggest ALS patients may benefit from longer-term treatment with NurOwn Poster highlighting design of planned Phase 3b NurOwn trial also presented NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular...BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting
NEW YORK, Sept. 24, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two abstracts featuring NurOwn® (MSC-NTF or Debamestrocel) at the 2024 Annual Northeastern...Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, whichRELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. announced the acceptance of several abstracts for presentation at the 2023 Northeast ALS Consortium Annual Meeting.
Read more news
Top Non-Profit & Charitable Organizations Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding The Northeast ALS Consortium
Sign Up For FreeTo access detailed company insights
NEALS is a global network dedicated to accelerating the discovery and delivery of effective treatments for Amyotrophic Lateral Sclerosis (ALS) through collaborative research and education. The organization connects researchers, clinicians, and individuals living with ALS to enhance clinical trial capabilities and provide educational resources. NEAL... Read More
